115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
抗体偶联药物及免疫治疗联合方案治疗三阴性乳腺癌的最新进展
Authors Chen H, Lu W, Zhou Y , Guo X, Wu S, Chen Y
Received 29 September 2025
Accepted for publication 4 January 2026
Published 14 January 2026 Volume 2026:18 571054
DOI https://doi.org/10.2147/BCTT.S571054
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Harikrishna Nakshatri
Huihui Chen,1– 3,* Wei Lu,2– 4,* Yunxiang Zhou,1– 3,* Xianan Guo,1– 3 Shijie Wu,1– 3 Yiding Chen1– 3
1Department of Breast Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 2Zhejiang Provincial Clinical Research Center for Cancer, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 3Cancer Center, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 4Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yiding Chen, Email ydchen@zju.edu.cn Wei Lu, Email 3120101767@zju.edu.cn
Abstract: Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive nature and lack of ER, PR and HER2 expression. Recent advances, however, are reshaping its treatment landscape, particularly with antibody-drug conjugates (ADCs) and immunotherapies. ADCs such as sacituzumab govitecan and datopotamab deruxtecan have demonstrated superior efficacy over standard chemotherapy in metastatic TNBC. Furthermore, combining these ADCs with immune checkpoint inhibitors is emerging as a powerful strategy to enhance antitumor activity, as evidenced by encouraging results from trials like MORPHEUS-panBC and BEGONIA. While most evidence currently centers on metastatic disease, these novel combinations are also being rapidly evaluated in neoadjuvant and adjuvant settings. Given this rapid progress, this article aims to summarize recent advances in ADCs and immunotherapy combinations for TNBC, discuss their synergistic mechanisms, and provide insights for future personalized therapeutic strategies.
Keywords: triple-negative breast cancer, antibody-drug conjugates, immunotherapy
1Department of Breast Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 2Zhejiang Provincial Clinical Research Center for Cancer, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 3Cancer Center, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 4Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yiding Chen, Email ydchen@zju.edu.cn Wei Lu, Email 3120101767@zju.edu.cn
Abstract: Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive nature and lack of ER, PR and HER2 expression. Recent advances, however, are reshaping its treatment landscape, particularly with antibody-drug conjugates (ADCs) and immunotherapies. ADCs such as sacituzumab govitecan and datopotamab deruxtecan have demonstrated superior efficacy over standard chemotherapy in metastatic TNBC. Furthermore, combining these ADCs with immune checkpoint inhibitors is emerging as a powerful strategy to enhance antitumor activity, as evidenced by encouraging results from trials like MORPHEUS-panBC and BEGONIA. While most evidence currently centers on metastatic disease, these novel combinations are also being rapidly evaluated in neoadjuvant and adjuvant settings. Given this rapid progress, this article aims to summarize recent advances in ADCs and immunotherapy combinations for TNBC, discuss their synergistic mechanisms, and provide insights for future personalized therapeutic strategies.
Keywords: triple-negative breast cancer, antibody-drug conjugates, immunotherapy